Eli Lilly and Company (NYSE:LLY) - SunTrust Banks lowered their Q2 2017 EPS estimates for Eli Lilly and in a research report issued on Monday. SunTrust Banks analyst J. Boris now anticipates that the company will earn $1.06 per share for the quarter, down from their previous forecast of $1.07. SunTrust Banks also issued estimates for Eli Lilly and’s FY2018 earnings at $4.42 EPS.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Eli Lilly and had a net margin of 10.13% and a return on equity of 26.64%. The business had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.22 billion. During the same quarter last year, the business earned $0.83 earnings per share. Eli Lilly and’s quarterly revenue was up 7.5% compared to the same quarter last year.
ILLEGAL ACTIVITY WARNING: “SunTrust Banks Weighs in on Eli Lilly and Company’s Q2 2017 Earnings (NYSE:LLY)” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/07/20/suntrust-banks-weighs-in-on-eli-lilly-and-companys-q2-2017-earnings-nyselly.html.
LLY has been the topic of several other reports. BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Barclays PLC boosted their price objective on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. Jefferies Group LLC restated a “buy” rating and issued a $96.00 price objective (up from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Citigroup Inc. boosted their price objective on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, April 19th. Finally, Morgan Stanley lowered shares of Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price objective on the stock. in a report on Monday, April 17th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $87.75.
Shares of Eli Lilly and (NYSE:LLY) opened at 84.23 on Tuesday. The stock has a 50 day moving average of $82.14 and a 200 day moving average of $81.04. The stock has a market cap of $88.97 billion, a P/E ratio of 40.73 and a beta of 0.35. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $86.72.
Several hedge funds have recently added to or reduced their stakes in the company. First Command Financial Services Inc. raised its stake in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the last quarter. Heritage Trust Co purchased a new stake in Eli Lilly and during the first quarter worth $135,000. Point72 Asia Hong Kong Ltd raised its stake in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the last quarter. LeJeune Puetz Investment Counsel LLC purchased a new stake in Eli Lilly and during the fourth quarter worth $136,000. Finally, Penserra Capital Management LLC raised its stake in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the last quarter. Hedge funds and other institutional investors own 75.47% of the company’s stock.
In related news, SVP Enrique A. Conterno sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the sale, the senior vice president now directly owns 114,217 shares in the company, valued at $9,452,598.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total transaction of $17,730,300.00. Following the sale, the insider now owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The disclosure for this sale can be found here. Insiders have sold 474,733 shares of company stock worth $39,634,487 over the last 90 days. Insiders own 0.20% of the company’s stock.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.47%. Eli Lilly and’s payout ratio is 100.48%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
